February 8, 2010 – Daiichi Sankyo Company, Limited, announced that its subsidiary, ASUBIO PHARMA CO., LTD. , submitted a New Drug Application in Japan for the manufacturing and marketing of SUN Y7017 (generic name: Memantine hydrocholoride), which was developed for the treatment of Alzheimer’s type Dementia (AD).
SUN Y7017 is an N-methyl-D-aspartate (NMDA) receptor antagonist developed by Merz Pharmaceuticals GmbH... [PDF] Daiichi Sankyo's Press Release -
